EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy

Francesco Giammarile, Arturo Chiti, Michael Lassmann, Boudewijn Brans, Glenn Flux

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Meta-iodobenzylguanidine, or Iobenguane, is an aralkylguanidine resulting from the combination of the benzyl group of bretylium and the guanidine group of guanethidine (an adrenergic neurone blocker). It is a noradrenaline (norepinephrine) analogue and so-called "false" neurotransmitter. This radiopharmaceutical, labeled with 131I, could be used as a radiotherapeutic metabolic agent in neuroectodermal tumours, that are derived from the primitive neural crest which develops to form the sympathetic nervous system. The neuroendocrine system is derived from a family of cells originating in the neural crest, characterized by an ability to incorporate amine precursors with subsequent decarboxylation. The purpose of this guideline is to assist nuclear medicine practitioners to evaluate patients who might be candidates for 131I-meta-iodobenzylguanidine to treat neuro-ectodermal tumours, to provide information for performing this treatment and to understand and evaluate the consequences of therapy.

Original languageEnglish
Pages (from-to)1039-1047
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume35
Issue number5
DOIs
Publication statusPublished - May 2008

Fingerprint

3-Iodobenzylguanidine
Neural Crest
Guidelines
Norepinephrine
Primitive Neuroectodermal Tumors
Guanethidine
Adrenergic Neurons
Neurosecretory Systems
Decarboxylation
Adrenergic Antagonists
Aptitude
Radiopharmaceuticals
Nuclear Medicine
Sympathetic Nervous System
Guanidine
Amines
Neurotransmitter Agents
Therapeutics
Neoplasms

Keywords

  • Guidelines
  • MIBG
  • Therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. / Giammarile, Francesco; Chiti, Arturo; Lassmann, Michael; Brans, Boudewijn; Flux, Glenn.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, No. 5, 05.2008, p. 1039-1047.

Research output: Contribution to journalArticle

Giammarile, Francesco ; Chiti, Arturo ; Lassmann, Michael ; Brans, Boudewijn ; Flux, Glenn. / EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. In: European Journal of Nuclear Medicine and Molecular Imaging. 2008 ; Vol. 35, No. 5. pp. 1039-1047.
@article{47fccca2ba8846b298e669b64ea31c10,
title = "EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy",
abstract = "Meta-iodobenzylguanidine, or Iobenguane, is an aralkylguanidine resulting from the combination of the benzyl group of bretylium and the guanidine group of guanethidine (an adrenergic neurone blocker). It is a noradrenaline (norepinephrine) analogue and so-called {"}false{"} neurotransmitter. This radiopharmaceutical, labeled with 131I, could be used as a radiotherapeutic metabolic agent in neuroectodermal tumours, that are derived from the primitive neural crest which develops to form the sympathetic nervous system. The neuroendocrine system is derived from a family of cells originating in the neural crest, characterized by an ability to incorporate amine precursors with subsequent decarboxylation. The purpose of this guideline is to assist nuclear medicine practitioners to evaluate patients who might be candidates for 131I-meta-iodobenzylguanidine to treat neuro-ectodermal tumours, to provide information for performing this treatment and to understand and evaluate the consequences of therapy.",
keywords = "Guidelines, MIBG, Therapy",
author = "Francesco Giammarile and Arturo Chiti and Michael Lassmann and Boudewijn Brans and Glenn Flux",
year = "2008",
month = "5",
doi = "10.1007/s00259-008-0715-3",
language = "English",
volume = "35",
pages = "1039--1047",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "5",

}

TY - JOUR

T1 - EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy

AU - Giammarile, Francesco

AU - Chiti, Arturo

AU - Lassmann, Michael

AU - Brans, Boudewijn

AU - Flux, Glenn

PY - 2008/5

Y1 - 2008/5

N2 - Meta-iodobenzylguanidine, or Iobenguane, is an aralkylguanidine resulting from the combination of the benzyl group of bretylium and the guanidine group of guanethidine (an adrenergic neurone blocker). It is a noradrenaline (norepinephrine) analogue and so-called "false" neurotransmitter. This radiopharmaceutical, labeled with 131I, could be used as a radiotherapeutic metabolic agent in neuroectodermal tumours, that are derived from the primitive neural crest which develops to form the sympathetic nervous system. The neuroendocrine system is derived from a family of cells originating in the neural crest, characterized by an ability to incorporate amine precursors with subsequent decarboxylation. The purpose of this guideline is to assist nuclear medicine practitioners to evaluate patients who might be candidates for 131I-meta-iodobenzylguanidine to treat neuro-ectodermal tumours, to provide information for performing this treatment and to understand and evaluate the consequences of therapy.

AB - Meta-iodobenzylguanidine, or Iobenguane, is an aralkylguanidine resulting from the combination of the benzyl group of bretylium and the guanidine group of guanethidine (an adrenergic neurone blocker). It is a noradrenaline (norepinephrine) analogue and so-called "false" neurotransmitter. This radiopharmaceutical, labeled with 131I, could be used as a radiotherapeutic metabolic agent in neuroectodermal tumours, that are derived from the primitive neural crest which develops to form the sympathetic nervous system. The neuroendocrine system is derived from a family of cells originating in the neural crest, characterized by an ability to incorporate amine precursors with subsequent decarboxylation. The purpose of this guideline is to assist nuclear medicine practitioners to evaluate patients who might be candidates for 131I-meta-iodobenzylguanidine to treat neuro-ectodermal tumours, to provide information for performing this treatment and to understand and evaluate the consequences of therapy.

KW - Guidelines

KW - MIBG

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=42149117808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149117808&partnerID=8YFLogxK

U2 - 10.1007/s00259-008-0715-3

DO - 10.1007/s00259-008-0715-3

M3 - Article

C2 - 18274745

AN - SCOPUS:42149117808

VL - 35

SP - 1039

EP - 1047

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 5

ER -